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Abstract
HIV-1 variants evolving in AIDS patients frequently show increased replicative capacity compared to those present during early
asymptomatic infection. It is known that late stage HIV-1 variants often show an expanded coreceptor tropism and altered Nef function. In
the present study we investigated whether enhanced HIV-1 LTR promoter activity might also evolve during disease progression. Our results
demonstrate increased LTR promoter activity after AIDS progression in 3 of 12 HIV-1-infected individuals studied. Further analysis
revealed that multiple alterations in the U3 core-enhancer and in the transactivation-response (TAR) region seem to be responsible for the
enhanced functional activity. Our findings show that in a subset of HIV-1-infected individuals enhanced LTR transcription contributes to
the increased replicative potential of late stage virus isolates and might accelerate disease progression.
© 2003 Elsevier Inc. All rights reserved.
Introduction
Variants of HIV-1 and SIV evolving during or after
progression to AIDS show genotypic and phenotypic dif-
ferences from early stage virus isolates. These changes seem
to be associated with increased virulence. It has been re-
ported that HIV-1 variants with enhanced replicative capac-
ity emerge before disease progression (Connor and Ho,
1994). AIDS develops faster in infants born to mothers with
low CD4 T-cell counts at the time of delivery (Tovo et al.,
1994). Experiments in the SIV-macaque model confirmed
that late virus variants show increased pathogenicity
(Kimata et al., 1999). It is known that an expanded core-
ceptor tropism (Van’t Wout et al., 1998; Xiao et al., 1998)
and functional changes in the nef gene contribute to the
pathogenic properties of late stage HIV and SIV variants
(Carl et al., 2001; Patel et al., 2002). However, it is currently
unclear whether alterations in the transcriptional activity of
the HIV-1 promoter, located in the 5 end of the long
terminal repeats (LTR), are also selected during disease
progression.
The HIV-1 LTR is approximately 640 bp in length and
segmented into the U3, R, and U5 regions. The U3 region is
further subdivided into the modulatory region, the enhancer
element comprising two NF-B-binding sites and the core
region with the TATAA box and three GC-rich binding sites
for Spl transcriptions factors (Gaynor, 1992). The R region
contains the 59 nucleotide trans-activation-responsive
(TAR) element forming a highly stable stem-loop RNA
structure (Feng and Holland, 1988). The TAR element is
important for Tat activation, efficient reverse transcription,
and efficient packaging of viral genomic RNA (Feng and
Holland, 1988; Harrich et al., 2000; Helga-Maria et al.,
1999).
The transcriptional activity of naturally occuring pro-
moter/TAR variants varies considerably (Delassus et al.,
1992; Michael et al., 1994; Estable et al., 1996; Kirchhoff et
al., 1997). A study of one single patient did not give indi-
cations for LTR alleles that were transcriptionally more
active during disease progression (Delassus et al., 1991).
Nevertheless, it remained unclear whether changes in tran-
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scriptional activity are selected during AIDS progression,
because either small numbers of patients were analyzed or
no sequential samples were available. Furthermore, most
data were obtained in immortalized cell lines transfected
with LTR reporter constructs and might not accurately re-
flect the situation in HIV-1-infected cells.
We analyzed the promoter activity of LTRs amplified
directly from peripheral blood mononuclear cells (PBMC)
derived from HIV-1-infected individuals prior to, during,
and after AIDS progression. We demonstrate that in some
patients transcriptional HIV-1 LTR activity is increased
after AIDS progression. Accordingly, emerging LTR vari-
ants with enhanced transcriptional and replicative capacity
might drive disease progression in a subset of HIV-1 in-
fected individuals.
Results
Alterations in LTR promoter activity during the course
of HIV-1 infection were investigated in the context of the
integrated provirus. We tried to ensure that the LTRs ana-
lyzed were representative for each patient and time point:(1)
DNA was isolated directly from patient PBMC samples
without any cell culture passage; (2) a relatively high quan-
tity of template DNA containing an average number of 130
proviral copies was used in a nested PCR approach to
ensure that multiple proviral LTR sequences are amplified,
and (3) mixtures of primary LTRs were inserted as a pool at
the 3 end of the pNL4-3.Luc.RE clone (Fig. 1A). Con-
trol experiments demonstrated that 95% of the proviral
constructs contained the correct inserts and that each plas-
mid preparation represented at least 100 independent
transformants (not shown).
Jurkat and U937 cells as well as primary human PBMC
and MDM were transduced with the pseudotyped HIV-1
particles (Table 1). During reverse transcription the patient-
derived 3 promoter sequences are copied to both the 5-
and 3-LTRs of the provirus allowing a readily quantitation
of the activity of the primary LTRs by Luciferase assay. The
Mann-Whitney test revealed a significant inverse relation-
ship between CD4 T-cell counts and LTR activities in both
PBMC (P  0.022) and MDM (P  0.005). To further
elucidate whether enhanced LTR activity is associated with
AIDS progression we categorized all patient samples into
two groups defined by CD4 T-cell counts greater (n  20)
or smaller (n  15) than 200/l at the time of PBMC
sampling. The transcriptional activity of late stage LTRs
was significantly higher compared to those obtained earlier
in infection in both PBMC (99.6  10.6% vs 67.1  7.5%;
P  0.0147; given are mean values  standard error) and
MDM (82.2  8.5% vs 53.4  3.9%; P  0.0021) (Fig.
1B). This relationship was also observed in Jurkat and U937
cell lines, but differences were less pronounced (60.5 
8.4% vs 44.0  3.7%; P  0.04 and 48.3  6.5% vs 36.1
 6.4%, P  0.118, respectively). Notably, the activity of
the primary LTR alleles was higher in primary cells than in
the transformed cell lines (PBMC, 81.0  39.9% compared
to 51.1  25.6% in Jurkat T cells; P  0.0005; and MDM,
65.7  28.8 compared to 41.3  22.7 in U937 cells; P 
0.0001; n  35; given are mean values  standard devia-
tion).
Thus, in primary cells the activity of LTRs obtained after
progression to AIDS was significantly higher than of those
obtained earlier in infection. However, this difference was
mainly due to strongly increased activity of LTR alleles
derived from individuals SP13, P7, and P10 (Table 1). LTR
alleles obtained from SP13 showed a slight increase in
activity from the early to the intermediate stage of infection
and a strong increase after AIDS progression. These differ-
ences were stronger in PBMC (5.5-fold) and Jurkat cells
(4-fold) than in MDM (3-fold) or U937 cells (2-fold). In
Fig. 1. Schematic presentation and transcriptional activity of proviral HIV-1 NL4-3 LTR variants. (A) The proviral NL4-3 reporter construct carries a
frame-shift mutation in the env open-reading frame as indicated by the asterisk and the nef gene is replaced by the luciferase gene (upper). Mutated LTRs
were inserted at the 3 end of the proviral genome using the XhoI and NcoI restriction sites indicated. The deletion in NL43(e-n-L)3LTR is marked by
a black bar. The NF-B and Sp1-binding sites, the TATA box, and the TAR region are shown. (B) The average promoter activities relative to the NL4-3
wt LTR (100%) were grouped according to the CD4 T-cell count at the time of PBMC sampling (Table 1) and analyzed as described in the methods section.
Indicated are mean values and the standard error of the mean.
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comparison, LTRs derived from subject P7 in 1993 were
generally about 3-fold more active than those derived from
the 1982 PBMC sample. The first two PBMC samples
analyzed from P10 were obtained when the CD4 T-cell
counts were high and the LTR alleles showed low activity.
In contrast, LTR sequences derived from a sample drawn in
1996 after AIDS progression were about 3-fold more active.
These results demonstrate strongly enhanced transcriptional
LTR activity at late stages in these three HIV-1-infected
individuals.
Next, we generated NL4-3 LTR variants containing an
intact env gene to analyze whether the increased LTR ac-
tivity is associated with enhanced replication. NL4-3 re-
combinants containing late stage LTRs replicated with en-
hanced efficiency in human PBMC (Figs. 2A–C). These
differences in replication efficiency were consistently ob-
served in four independent experiments performed in
PBMC derived from different blood donors. Notably, we
did not observe significant differences in the efficiency of
viral replication with NL4-3 variants containing sequential
LTR alleles derived from individuals P13, P15, and P18,
which did not show increased transcriptional activity after
AIDS progression (Figs. 2D–E). Thus, the increased tran-
scriptional LTR activity observed in some HIV-1-infected
individuals after progression to AIDS is associated with
enhanced replicative capacity.
We also investigated which sequence alterations might
be responsible for the increase in functional LTR activity. In
all three individuals substantial differences were observed
between the early and late stage LTR sequences (Fig. 3).
Table 1
Promoter activities of LTR alleles obtained at different stages of HIV-1 infection
Patient Samplinga Ageb CD4 counts LTR promoter activityc
No./mm3 % Jurkat U937 PBMC MDM
SP8 1984 12 616 27 81  15 73  2 105  14 77  9
1987 14 474 29 50  8 50  7 79  6 50  11
1996 24 39 4 70  12 80  3 101  12 43  9
SP13 1984 6 1622 53 39 4 46  7 22  8 43  6
1990 11 722 29 58  5 73  4 42  3 33  3
1993 14 66 6 155  18 103  1 122  15 139  21
P5 1983 11 616 25 61  10 28  6 100  34 60  5
1991 18 121 8 82  6 38  1 149  21 119  13
1995 22 11 1 75  9 26  3 141  19 94  22
P7 1982 8 1000 48 16  2 15  1 47  4 27  3
1985 11 822 33 43  4 33  3 87  7 55  14
1993 18 7 1 56  1 48  2 140  15 73  24
P8 1983 43 526 26 26  3 21  2 103  7 62  4
1987 47 126 6 50  2 71  3 102  15 80  12
1989 49 12 1 35  2 45  5 139  5 80  3
P9 1984 45 636 37 64  8 69  8 158  13 80  12
1989 50 118 12 69  16 80  5 166  29 112  7
1998 58 95 9 59  4 58  5 83  7 144  7
P10 1984 3 1021 40 36  4 17  3 31  7 45  4
1986 4 1357 34 26  4 14  3 27  3 29  3
1996 14 9 1 91  9 45  8 76  8 62  4
P13 1985 9 598 16 44  6 21  2 79  16 45  6
1991 15 222 6 49  3 34  2 64  5 39  2
1995 20 11 2 35  2 27  2 58  3 37  6
P15 1984 27 657 36 19  3 18  2 49  4 50  4
1986 29 591 37 22  1 63  12 52  4 60  7
1990 33 59 3 20  1 38  2 60  6 63  5
P16 1985 22 771 27 51  3 29  5 52  4 80  15
1987 24 384 28 41  1 29  4 31  5 88  12
1990 27 89 2 45  3 22  4 35  1 72  15
P17 1984 18 666 28 55  5 37  4 51  6 37  3
1989 23 15 4 51  5 20  2 60  7 55  21
P18 1984 16 1017 23 46  9 29  2 80  12 48  6
1986 17 456 10 52  8 23  4 83  15 59  4
1988 19 15 1 35  4 23  1 62  2 60  8
a Year of PBMC sampling for PCR analysis.
b Age of the HIV-1-infected individuals at the date of PBMC sampling.
c Average values and standard deviations for transcriptional activity. Values are given relative to the NL4-3 activity and were determined as described under
Materials and Methods. Results were obtained from triplicate transductions and were confirmed in two to four independent experiments. The activity of the
NL43(e-n-L)3LTR control control construct was consistently 1% of the wild type NL4-3 activity.
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The consensus 84 and 93 SP13 LTR alleles differed by a
total of 39 nucleotide substitutions (Fig. 3A). Most alter-
ations were located in the upstream modulatory U3 region
and affected the potential NF-AT, C-ETS, and USF-binding
sites. Furthermore, late SP13 LTRs contained changes in the
Sp1-3 site as well as in the TAR element. Two groups of
sequences were obtained from the P7-82 PBMC samples.
Three of eight LTR alleles (consensus designated as P7–
82B) showed high sequence homology to the later stage
LTRs. The remaining five clones (P7–82A) differed by at
least 32 nucleotide substitutions from the P7–93 consensus
sequence and contained two G3A nucleotide substitutions
at the 5 base of the TAR region, a single mutation in the
TAR hexanucleotide loop, and numerous substitutions in
the NF-kB and SpI-binding sites resulting in a substantially
higher GC content (Fig. 3B). Little sequence variation was
observed between LTRs derived from P10 during asymp-
tomatic infection in 84 and 86 (Fig. 3C). However, the
P10–96 LTR sequences differed by approximately 26 nu-
cleotide substitutions from the early sequences and con-
tained several alterations increasing the GC content in the
SpI sites. Thus, multiple changes in the U3 and R regions of
the LTR, particularly in the core enhancer-promoter and
TAR elements, were selected during the course of infection
in subjects SP13, P7, and P10. For comparison, we also
investigated LTR sequences derived from P13, P15, and
P18, which did not show increased LTR activity after pro-
gression to AIDS. Notably, late stage LTR sequences de-
Fig. 3. Alignment of sequential LTR promoter/TAR consensus sequences. For clarity only consensus LTR sequences obtained from the sequential SP13 (A),
P7 (B), P10 (C), P13 (D), P15 (E), and P18 (F) PBMC samples are shown. Each consensus sequence was derived from five to eight individual clones analyzed.
Sequences are aligned with the LTR sequence derived from the early stage PBMC sample. Two different groups of sequences were obtained from the P7–82
PBMC samples; five represented P7–82A and three P7–82B LTR alleles. Dots indicate sequence identity and dashes nucleotide deletions. The NF-B-
binding motifs, the Sp1 sites, and the TATAA sequence are underlined and shaded. The positions of the start of transcription, the TAR core region, and the
TAR bulge and loop sequences are also indicated.
Fig. 2. Replication of sequential HIV-1 LTR variants in PBMC. Cells were infected with HIV-1 NL4-3 variants containing primary LTRs derived from
subject SP13 (A), P7 (B), P10 (C), P13 (D), P15 (E), and P18 (F). PBMC were infected with virus stocks containing 100 ng of p24 antigen immediately after
isolation and stimulated 3 days later. Viral replication was determined by reverse-transcriptase assay. Shown are the results of one representative experiment
out of four performed. Abbreviations: RT, reverse transcription; PSL, photon-stimulated luminescence. Symbols: , NL4-3 wt; ‚, early; ƒ, intermediate;
Œ, late LTR alleles; and , uninfected cells.
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rived from these individuals did not contain changes in-
creasing the GC content of the Sp1-binding sites or
alterations in the base, bulge, and the hexanucleotide loop
sequence of the TAR region compared to the early LTR
alleles (Figs. 3D–F). Finally, we analyzed the activity of
time-point representative individual LTR alleles. Consistent
with the previous results (Table 1), early stage LTRs alleles
showed lower functional activity than the late stage LTRs
(Fig. 4). Concordant with the sequencing data the P7–82A
LTRs containing mutations at the base of the TAR element
were severely impaired in transcriptional activity, whereas the
P7–82B LTRs were functionally active (Fig. 4). Thus, the low
average activity of the early P7–82 LTR alleles is due to a high
proportion of clones containing attenuating mutations.
Discussion
A variety of viral factors, e.g., escape from neutralizing
Ab and CTL responses, antiviral drug resistance, an ex-
panded cell, and coreceptor tropism or altered Nef function,
might mediate a selective advantage allowing a certain
HIV-1 quasispecies to become predominant in vivo. Obvi-
ously, these variations in biological viral properties can be
selected individually or in various combinations. Subopti-
mal LTRs might become predominant if the viral genome
contains mutations elsewhere resulting in a stronger growth
advantage. Therefore, it is expected that LTR activities were
only increased at late stages of infection in a minority of
HIV-1 infected individuals. Many different viral and host
factors need to be analyzed to better understand the complex
interplay between HIV-1 and its host. This study demon-
strates that in some HIV-1-infected individuals alterations
in the LTR contribute to the increased replicative capacity
of late stage virus isolates. One possible reason for their
selection is that with a loss of immune surveillance, viral
antigens expressed in cells would no longer label a cell for
lysis. Therefore, unrestrained transcription may no longer
carry a selective disadvantage.
We analyzed proviral DNA sequences rather than
genomic RNA sequences because of the availability of
samples. A possible disadvantage is that archival LTR se-
quences from both intact and defective proviruses are am-
plified. However, all samples were obtained from progress-
ing individuals with ongoing viral replication and the half-
life time of infected PBMC in the periphery should be only
about 2 days (Perelson et al., 1996). One important question
is whether the proviral LTR sequences analyzed are repre-
sentative for each patient and time point. Clearly, the pos-
sibility that relevant sequence variants are missed cannot be
excluded in this type of analysis. However, we feel that
most likely the LTRs analyzed in our study were represen-
tative because PCR amplification was performed using high
quantities of DNA derived directly from patient PBMC
samples and complex pools of primary LTRs were inserted
into the proviral constructs. Quantitative analysis of eight
template DNA samples revealed an average number of 259
proviral copies per microgram DNA. Furthermore, indepen-
dent PCR amplifications from the same DNA samples
yielded LTR sequences that were both patient and time-
point specific (data not shown). Taken together, our findings
indicate that the LTRs analyzed are representative for the
majority of integrated HIV-1 promoters present in the
PBMC samples investigated.
Several patients were also analyzed for changes in Nef
and Env function (summarized in Table 2). Late stage
HIV-1 variants detected in individuals SP13 and P10, in
whom LTR activity was strongly increased after AIDS
progression, also showed an expanded coreceptor tropism.
In comparison, X4- or dual-tropic variants were only de-
tected at late stages in one of six HIV-1-infected individuals
tested, who did not show an increase in transcriptional LTR
activity. Simm et al. (1996) found that LTRs from X4- and
R5-tropic HIV-1 isolates do not differ in transcriptional
activity. However, only one AIDS patient and two asymp-
tomatic individuals were analyzed. Thus, it needs further
investigation to clarify whether the emergence of rapidly
replicating cytopathic X4- or dual-tropic HIV-1 isolates
frequently coincides with increased transcriptional LTR ac-
tivity. Perhaps an altered tropism may necessitate modula-
tion of LTR activity as different cell types are infected. In
subjects P7 and P10 late stage nef alleles showed a decrease
in class I MHC-I down-regulation and an increased ability
to down-modulate CD4 and to stimulate viral replication
(Carl et al., 2001). Thus, in some HIV-1-infected individu-
als, e.g., P10, changes in Env, Nef, and LTR function
contribute simultaneously to the virulence of late stage
HIV-1 variants.
Our data suggest that in subjects SP13, P7, and P10 at
least three different mechanisms might contribute to the
increased activity of LTRs obtained after progression to
Fig. 4. Promoter activity of individual time-point representative HIV-1
LTRs. PBMC were transduced with the pseudotyped luciferase reporter
viruses. Promoter activities together with standard deviation are shown
relative to the NL4-3 wt LTR activity (100%). Values were derived from
triplicate transductions with each individual LTR allele. The sequences of
the LTR variants tested are shown in Fig. 3. Similar results were obtained
in one independent experiment and in Jurkat or U937 cells. Control, cells
were transduced with the NL43(e-n-L)3LTR construct.
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AIDS. First, late stage LTRs frequently contained substitu-
tions in the Sp1-binding sites increasing the GC content in
the basal promoter region and presumably enhancing the
affinity for the cellular transcription factor Sp1 (Jones et al.,
1986). Second, early stage TAR sequences frequently con-
tained mutations at the 5 base of the TAR region impairing
perfect pairing with the 3 base. In contrast, all late LTR
alleles contained perfectly matching 5- and 3-base TAR
regions (Fig. 4). Thus, alterations at the base of the TAR
element might attenuate LTR activation by Tat and the
efficiency of reverse transcription. Third, several mutations
in the hexanucleotide loop region of TAR, shown to de-
crease the level of cooperative Cyclin T1 and Tat binding
(Dingwall et al., 1990; Richter et al., 2002), were exclu-
sively observed in early stage LTR alleles. Further studies
with larger numbers of samples are required to clarify
whether some individuals are initially infected with HIV-1
variants containing suboptimal promoter/TAR regions or
whether forms containing highly active LTR emerge during
or after AIDS progression.
Relative to the wild-type NL4-3 LTR, the patient-derived
LTRs showed significantly higher activity in human PBMC
and MDM, compared to Jurkat and U937 cells, respectively.
Furthermore, while a trend toward higher activity of late
stage LTR alleles was also observed in immortalized cell
lines, this was much more significant in primary cells. Thus,
some properties of the patient-derived LTRs seem to be
more relevant for efficient transcription in primary human
cells than in immortalized cell lines.
Dissecting the relative importance of the various pheno-
typic changes occurring during the course of infection for
HIV-1 virulence and hence disease progression will be a
challenging task. In each case, enhanced transcriptional
LTR activity would directly lead to increased virus produc-
tion and should result in higher viral load and accelerate
AIDS progression. The phenotypic changes observed in
HIV-1 infection (Van’t Wout et al., 1998; Xiao et al., 1998;
Carl et al., 2001) and experimental studies in the SIV/
macaque model (Kimata et al., 1999; Patel et al., 2002)
strongly suggest that viruses frequently become more viru-
lent during progression to AIDS. Nevertheless, there is no
evidence for an overall increase in virulence in the HIV-1-
infected population. It will be interesting to elucidate the
different selective forces “counterselecting” the properties
that make late stage isolates highly aggressive. A better
knowledge of the complex interplay between the virus and
the host might lead to new approaches allowing a delay or
even prevention of disease progression.
Materials and methods
Study population
Samples were obtained from 12 individuals in the cohort
monitored since 1983 at the New England Comprehensive
Hemophilia Center at the UMass/Memorial Health Center,
Worcester, Massachusetts (Table 1). These individuals were
selected by a CD4 T-cell profile that showed an early rapid
decline or a clear time point of inflection. Samples generally
predated the use of highly active antiretroviral therapy.
Plasma viral RNA levels were not available for early time
points and are not included in the analysis. References to
“early” and “late” disease pertain to sample time points
when CD4 T-cell counts were higher than or less than
200/l, respectively. All participants have given informed
consent to these studies with the approval of the institutional
review board on the conduct of research on human subjects
at the UMass Medical School.
Viral load
Proviral DNA copy numbers in patients followed by the
Worcester cohort were estimated using a modification of the
Table 2
Alterations in Env, Nef, and LTR function during the course of HIV-1 infection
Sample LTR activitya Coreceptor
tropismb
Nef functionc
CD4 Class I MHC Infectivity Replication
SP13–84 1.00 R5 n.d. n.d. n.d. n.d.
SP13–90 1.91 R5 n.d. n.d. n.d. n.d.
SP13–93 5.55 R5X4 n.d. n.d. n.d. n.d.
P7–82 1.00 R5 1.00 1.00 1.00 1.00
P7–85 1.85 R5 1.37 0.62 2.20 1.07
P7–93 2.98 R5 1.12 0.23 2.94 1.60
P10–84 1.00 n.d. 1.00 1.00 1.00 1.00
P10–86 0.89 R5 1.03 2.68 1.22 3.65
P10–96 2.45 R5X4 4.74 0.16 1.41 6.95
a Values give promoter activity in PBMC relative to the activity of pooled LTR alleles derived from the early patient sample.
b Full-length patient-derived env genes were cloned into into the NL4-3 backbone and the coreceptor tropism was determined with X4.15 and R5.3 cells
coexpressing CD4 and R5 or X4 as described elsewhere (Mu¨nch et al., 2002).
c The in vitro activities of these nef alleles have been described previously (Carl et al., 2001). The functional activity is shown relative to the early stage
nef alleles.
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Amplicor HIV-1 test system (Roche Diagnostics Systems,
Inc, Branchburg, NJ) as described (Greenough et al., 1999).
Quantitative analysis of viral RNA loads was performed
using the Amplicor HIV-1 Monitor assay (Roche Diagnos-
tics Systems) following the manufacturers instructions.
HIV-1 LTR mutant construction
PBMCs were isolated from patient blood samples by
centrifugation through Ficoll-Histopaque density gradients.
Genomic DNA was extracted by standard methods from
freshly purified PBMC, or from samples continuously fro-
zen at 70°C since collection. A nested PCR method was
employed to amplify the LTR region using the outer primer
set pF1 (5-GCAGTAGCTGAGGGGACAGATAGG-3)
and K114 (5-CATGCCATGGACTGCTAGAGATTTTC-
CACACTG-3) and the inner primer pair K116-nefXho
(5-GGTGGGAGCAGTATCTCGAGACC-3) and K112
(5-CATGCCATGGTCTGAGGGATCTCTAGTTACCA-
GAGT-3). The XhoI and NcoI sites (underlined) were used
to replace the HIV-1 NL4-3 3-LTR with the patient-derived
sequences (Fig. 1A). For each sample 0.5 g of template
DNA was used for amplification. The PCR products were
inserted as a pool into the pNL4-3.Luc.RE clone con-
taining the luciferase reporter gene and a disrupted env gene
(Connor et al., 1995). Cloning efficiencies were determined
as described previously (Carl et al., 2001). Briefly, aliquots
of the transformed supercompetent E. coli XL-2 (Strat-
agene) were plated on LB-Amp dishes to assess the trans-
formation efficiency, and the remaining 90% of the trans-
formed bacteria were used for direct inoculation of medium-
scale plasmid preparations. The percentage of the plasmid
population containing an HIV-1 nef insert was estimated by
restriction and PCR analysis. NL43(e-n-L)3LTR miss-
ing the U3 sequences upstream of the TATA box served as
negative control (Fig. 1A). Sequencing was performed with
the PRISM kit (Perkin-Elmer, Foster City, CA) on an Ap-
plied Biosystem 373 DNA sequencer. Proviral constructs
containing an intact env gene were generated by standard
cloning techniques.
Virus stocks
Generation of virus stocks was performed as described
(Hiebenthal-Millow and Kirchhoff, 2002). Briefly, for the
generation of pseudotyped viral particles, 293T cells were
cotransfected with the proviral constructs and a plasmid
expressing the Env protein of the vesicular stomatitis virus
(VSV-G). For the production of replication-competent vi-
rus, 293T cells were transfected with 10 g of the full-
length NL4-3 proviral constructs. Viral stocks were stored
in aliquots at 80°C. The p24 antigen concentrations were
quantitated by using an HIV-ELISA provided by the NIH
AIDS Research and Reference Reagent Program (Rock-
ville, MD).
Cell culture
293T cells were maintained in DMEM supplemented
with 10% FCS. Jurkat and U937 cells were kept in RPMI
1640 with 10% FCS. PBMC were isolated using lympho-
cyte separation medium (Biochrom KG, Germany), stimu-
lated 3 days with 4 g/ml PHA and cultured in RPMI 1640
medium with 20% FCS and 50 U interleukin-2 (IL-2)/ml.
For MDM isolation, cells were isolated from fresh blood as
described above. Cells (7.5  105) were seeded in 48-well
dishes and cultured for 1 week in RPMI 1640 supplemented
with 10% human serum (GibcoBRL, Carlsbad, CA), 50
U/ml GM-CSF (Boehringer Mannheim, Germany), and an-
tibiotics to allow monocyte differentiation and adherence to
the plates. Subsequently, nonadherent cells were removed
by extensive washing with PBS.
Reporter assays
Jurkat and U937 cells were seeded at 1  105 in 24 well
dishes, PBMC at 1  106, and MDM at 2  105 in 48 well
dishes and transduced in triplicates with aliquots of virus
stocks containing 600 ng p24 antigen in a total volume of
250 or 150 l medium, respectively. At 4 h after transduc-
tion medium was added to a final volume of 1 ml or 500 l,
respectively. At 3 or 4 days after infection the cells were
pelleted, washed once with phosphate-buffered saline, and
resuspended in 50 l lysis buffer (Promega, Madison, WI).
Cell debris was removed by centrifugation and 5 l of the
supernatant was used to determine the total protein concen-
tration with a commercial reagent (Bio-Rad Laboratories,
CA). Luciferase assays were performed with the Promega
assay system as recommended by the manufacturer.
Viral replication
PBMC were infected immediately after isolation with
aliquots of viral stocks containing 100 ng p24 antigen.
Three days postinfection cells were stimulated with PHA (4
g/ml, Sigma) for 3 days, washed, and maintained in RPMI
1640 supplemented with 20% FCS and 50 U/ml IL-2. Cell
culture supernatants were sampled at regular intervals
and stored at 20°C. Virus production was measured
by reverse-transcriptase assay as described elsewhere
(Hiebenthal-Millow and Kirchhoff, 2002). At the end of
culture PCR amplification and sequence analysis of the
5-LTRs were performed to verify that the patient-de-
rived LTR sequences were still present and that no re-
combination with wild-type NL4-3 LTR sequences oc-
curred.
Statistical methods
The mean and median LTR activities for subgroups de-
fined by CD4 T-cell numbers at the time of PBMC sam-
pling were compared by using Student’s t test with Welch’s
117K. Hiebenthal-Millow et al. / Virology 317 (2003) 109–118
correction. Similar results were obtained with the Mann-
Whitney test. The software package StatView version 4.0
(Abacus Concepts, Berkeley, CA) was used for all calcula-
tions.
GenBank accession numbers
The LTR sequences analyzed in this study have been as-
signed Genbank Accession Nos. AY376247 to AY366266.
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